Turkish retrospective review of 30 axSpA/PsA pts w/ Hx of prior malignancy and went on Rx w/ secukinumab betw 2018-2024. After mean F/U of ~ 30mo, SEC retention was 90% @12 mos & 81% @24 mos. There was only 1 local tumor recurrence w bladder carcinoma https://t.co/t7tqPtHOff https://t.co/wfAxwEsZLK